Synthetic Biologics Inc. (NASDAQ: SYN) stock gained by 8.09% at last close whereas the SYN stock price declines by 0.54% in the pre-market trading. Synthetic Biologics is a clinical-stage business that uses the microbiome to create medicines to prevent and cure GI illnesses in regions where there is a significant unmet need.
>> 7 Top Picks for the Post-Pandemic Economy <<
What’s up with SYN stock?
Patient dosing and monitoring in Synthetic Biologics’ Phase 1 open label, single-ascending dose (SAD) clinical study of SYN-020 intestinal alkaline phosphatase has been concluded (IAP). SYN-020 was administered orally in single dosages ranging from 5 mg to 150 mg daily to 24 healthy adult volunteers in Phase 1 SAD trial. SYN-020 had a positive safety profile, was well tolerated at all dosage levels, and no side effects were linked to the study medication, according to early data. There were no significant side effects recorded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
During the third quarter of 2021, a second Phase 1 clinical trial to assess the efficacy, acceptability, and biodistribution of multiple-ascending doses of SYN-020 in healthy volunteers is planned to begin. The clinical trial’s topline findings are anticipated in the second quarter of 2022. SYN-020 is being developed in many possible therapeutic indications, including celiac disease, nonalcoholic fatty liver disease, and radiation enteropathy, in both Phase 1 SAD and MAD trials. Also, indications for treating and preventing metabolic and inflammatory diseases linked to aging, which are backed up by SYN’s partnership with Massachusetts General Hospital.
Steven A. Shallcross, CEO of Synthetic Biologics commented,
SYN-020 is a successful, versatile program with the capability to be a multi-indication, platform therapeutic willing to address a significant unmet need for innovative new therapies attacking GI inflammation disorders, such as celiac disease, NAFLD, and age-related metabolic and inflammatory diseases. By 2023, the number of cases of celiac disease in the United States is anticipated to reach 4.3 million, offering a huge market potential for a highly differentiated product like SYN-020. They are delighted by the good Phase 1 results and look forward to the further development of SYN-020.
>> 7 Top Picks for the Post-Pandemic Economy <<
Upcoming Event for SYN stock
Synthetic Biologics has announced that on Thursday, August 5, 2021, the company will reveal its operational highlights and financial performance for the quarter ending June 30, 2021.
